Also published in GlobeNewswire:
Rand Logistics Announces Organizational and Corporate Governance Changes
x hide permanently

Caladrius Biosciences Appoints Dr. Michael H. Davidson to Board of Directors

GlobeNewswire

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not simply manage, disease, today announced the appointment of Michael H. Davidson, MD to its Board of Directors. Dr. Davidson, an industry leader and expert in preventative cardiology and lipidology, is the Founder and Chief Scientific Officer of Corvidia Therapeutics, which recently announced its sale to Novo-Nordisk for $2.1 billion...

Mentions: Nasdaq Sale Founder